Digital Health & Discovery Platform
@dhdp-ca.bsky.social did:plc:w6uj7tqg2364o3cs23opmtia
We combine Canadian expertise in artificial intelligence (AI) and precision medicine to improve healthcare for Canadians. www.dhdp.ca Led by the Terry Fox Research Institute @terryfoxresearch.bsky.social
Sur Bluesky depuis le
- Abonnés
- 158
- Abonnements
- 363
- Posts
- 413
- Jours dans les classements
- 0
Résumé
Digital Health & Discovery Platform (@dhdp-ca.bsky.social) est sur Bluesky depuis le 21 avril 2025. Le compte a 158 abonnés, suit 363 comptes et a publié 413 posts.
Présence dans les classements
Les meilleurs jours où les posts de ce compte sont entrés dans le top quotidien de Debya.
Ce compte n’est encore apparu dans aucun classement quotidien.
Posts aimés récemment
J’aime publics du réseau Bluesky.
HAPPENING NOW: Fueling Digital Health Innovation How can a $25M gift accelerate cancer research through AI, machine learning and big data? Charles Crosbie of the Terry Fox Research Institute explores how this investment can advance innovation across Canada’s public and private sectors. #PACT2026
Voir le post🍁 Investing in future precision onocology leaders 🍁 MOHCCN is awarding $2.1 million to four outstanding early-career clinician-scientists through the 2026 Clinician-Scientist Awards. Read the full announcement: www.marathonofhopecancercentres.ca/impact/news-...
Voir le postIs treatment working? Could it come back? For young people with Hodgkin lymphoma, uncertainty can be overwhelming. Dr. Tomohiro Aoki, a 2026 MOHCCN Clinician-Scientist Awardee, is developing a blood test to monitor treatment response and detect relapse earlier. Learn more: tinyurl.com/eskd7r68
Voir le postThe immune system is designed to fight disease. So why can some brain tumours evade its attack? Dr. Charles Couturier, a neurosurgeon and researcher at McGill University, is working to find answers with support from a 2026 MOHCCN Clinician-Scientist Award. Learn more: tinyurl.com/5cvr3m5e
Voir le postHow do we know when a more advanced treatment is the better choice? 2026 MOHCCN Clinician-Scientist Awardee, Dr. Rachel Glicksman will lead the ASPIRE clinical trial to assess whether adaptive SBRT improves patients’ quality of life and if it's cost-effective. Learn more: tinyurl.com/3zwarwen
Voir le post
Comptes bloqués
Sur Bluesky, les blocages sont publics.
Ce compte ne bloque personne.